Collegium (COLL) Q2 Revenue Jumps 29%

Collegium Pharmaceutical (NASDAQ:COLL), a specialty pharmaceutical firm focused on pain management and neuropsychiatry, reported its Q2 2025 earnings on August 7, 2025. GAAP revenue was $188.0 million and non-GAAP earnings per share was $1.68, both above Wall Street analysts' projections of $180.9 million (GAAP) revenue and $1.62 non-GAAP EPS, respectively. Net product revenue (GAAP) rose 29% year-over-year, fueled by ongoing growth in ADHD product Jornay PM. Despite top-line and earnings outperformance, rising operating expenses and declining GAAP net income highlight cost pressures. Overall, the company delivered a strong operating quarter, raised its full-year 2025 financial guidance, and continued to reinvest in commercial expansion. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Collegium Pharmaceutical operates in the specialty pharmaceutical sector, focusing on developing and commercializing medications for pain management and central nervous system disorders. Its chief products include pain drugs like Belbuca (a buprenorphine buccal film), Xtampza ER (an extended-release abuse-deterrent oxycodone), and Nucynta (tapentadol extended and immediate release tablets), as well as the ADHD treatment Jornay PM (a delayed-release, extended-release methylphenidate capsule).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool